PIPELINE OVERVIEW

Best-in-class topical drugs that patients want to use

Skin and eye diseases negatively affect the appearance quality of life and patients are highly involved in the choice of therapy. Patients want therapies that are safe, efficacious and convenient to use in everyday life – in particular in the case of life-long chronic diseases.

>85% of patients with psoriasis or atopic dermatitis use topicals. The most potent and safe topicals are superior to oral and biologic treatments in clearing skin within the first 4 weeks of treatment. However, the majority of patients do not like to use such topical drugs because they are greasy Vaseline-like ointments that stain clothes and bedding. Patients have to plan their daily routines and social life around application of the drug, which significantly affects quality of life and patient compliance. The result is patient dissatisfaction and sub-optimal real-life efficacy of the prescribed therapies. These dynamics motivate patients to shift to more elegant but inferior topicals and/or much more expensive systemic therapies.

PAD™ Technology uniquely enables formulation of best-in-class API’s into differentiated elegant cream based drugs and eye drop with an unsurpassed combination of efficacy, safety and patient acceptability.

Our current pipeline is comprised of development programs in psoriasis, atopic dermatitis and dry and sensitive skin and eyes:

OVERVIEW

NB! Timeline subject to regulatory feedback and continued funding.

MC2-01 cream

Calci/BDP combination is the best-in-class topical therapy for mild to moderate psoriasis.

Read more

Active Ingredients: Calcipotrience + betamethasone
Indication: Psoriasis Mild to mod.
Patient Pool: ~12M

MC2-01 cream

Calci/BDP combination is the best-in-class topical therapy for mild to moderate psoriasis.

Read more

Active Ingredients: Calcipotrience + betamethasone
Indication: Psoriasis Mild to mod.
Patient Pool: ~12M

© mc2 therapeutics 2020